CUE (Cue Biopharma) Beneish M-Score: 1.03 (As of Jun. 25, 2026)

What is Cue Biopharma Beneish M-Score?

Cue Biopharma CUE -0.27% 59 Beneish M-Score is 1.03 as of Jun. 25, 2026. GuruFocus rates CUE with a GF Score™ of 59/100 and a GF Value™ of $62.11 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 831 Biotechnology companies, Cue Biopharma ranks worse than 86.88% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 1.03 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Cue Biopharma's Beneish M-Score or its related term are showing as below:

CUE' s Beneish M-Score Range Over the Past 10 Years
Min: -8.71 Med: -1.77 Max: 9.81
Current: 1.03

During the past 11 years, the highest Beneish M-Score of Cue Biopharma was 9.81. The lowest was -8.71. And the median was -1.77.

Cue Biopharma Beneish M-Score Related Terms

Cue Biopharma Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Cue Biopharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cue Biopharma Beneish M-Score Chart

Cue Biopharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Beneish M-Score

Get a 7-Day Free Trial

0.45

-6.71

5.09

-2.92

0.11

Cue Biopharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Beneish M-Score	Get a 7-Day Free Trial															-4.36	-4.17	-4.28	0.11	1.03

CUE vs TELO, ACET, AARD: Beneish M-Score Comparison

For the Biotechnology subindustry, Cue Biopharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cue Biopharma Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cue Biopharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Cue Biopharma's Beneish M-Score falls into.

Save Embed

59GF Score

Cue Biopharma Inc CUE

Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cue Biopharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Cue Biopharma for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 * 1

0.528 * 1

0.404 * 0.2865

0.892 * 4.096

0.115 * 0.742

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 * 0.2718

4.679 * 0.160475

0.327 * 0.4262

1.03

This Year (Mar26) TTM:

Last Year (Mar25) TTM:

Total Receivables was $7.25 Mil.
Revenue was 5.686 + 21.942 + 2.149 + 2.954 = $32.73 Mil.
Gross Profit was 5.686 + 21.942 + 2.149 + 2.954 = $32.73 Mil.
Total Current Assets was $26.39 Mil.
Total Assets was $30.88 Mil.
Property, Plant and Equipment(Net PPE) was $3.61 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.53 Mil.
Selling, General, & Admin. Expense(SGA) was $16.22 Mil.
Total Current Liabilities was $7.39 Mil.
Long-Term Debt & Capital Lease Obligation was $1.88 Mil.
Net Income was -5.178 + 1.585 + -7.448 + -8.482 = $-19.52 Mil.
Non Operating Income was 0.01 + 0.02 + -0.051 + 0 = $-0.02 Mil.
Cash Flow from Operations was -10.942 + -1.076 + -9.024 + -3.415 = $-24.46 Mil.

Total Receivables was $0.00 Mil.
Revenue was 0.421 + 1.576 + 3.336 + 2.658 = $7.99 Mil.
Gross Profit was 0.421 + 1.576 + 3.336 + 2.658 = $7.99 Mil.
Total Current Assets was $15.93 Mil.
Total Assets was $22.25 Mil.
Property, Plant and Equipment(Net PPE) was $4.11 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.38 Mil.
Selling, General, & Admin. Expense(SGA) was $14.57 Mil.
Total Current Liabilities was $15.50 Mil.
Long-Term Debt & Capital Lease Obligation was $0.18 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(7.25 / 32.731)	/	(0 / 7.991)
	=	0.221503	/	0
	=	1

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(7.991 / 7.991)	/	(32.731 / 32.731)
	=	1	/	1
	=	1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (26.392 + 3.606) / 30.877)	/	(1 - (15.931 + 4.112) / 22.254)
	=	0.028468	/	0.099353
	=	0.2865

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	32.731	/	7.991
	=	4.096

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(2.383 / (2.383 + 4.112))	/	(3.527 / (3.527 + 3.606))
	=	0.366898	/	0.494462
	=	0.742

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(16.218 / 32.731)	/	(14.566 / 7.991)
	=	0.495494	/	1.822801
	=	0.2718

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((1.878 + 7.391) / 30.877)	/	((0.176 + 15.498) / 22.254)
	=	0.300191	/	0.704323
	=	0.4262

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-19.523 - -0.021	-	-24.457)	/	30.877
	=	0.160475

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Cue Biopharma has a M-score of 1.03 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →

What does a Beneish M-Score of 1.03 mean?

Cue Biopharma (CUE) has a Beneish M-Score of 1.03 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Cue Biopharma and its competitors. According to the industry distribution chart, Cue Biopharma ranks #722 out of 831 companies in the Biotechnology industry, placing it in the top 86.9%.

Is Cue Biopharma's Beneish M-Score too high?

Cue Biopharma's current Beneish M-Score is 1.03. Based on the distribution chart, Cue Biopharma ranks #722 out of 831 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cue Biopharma has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Cue Biopharma's Beneish M-Score compare to TELO and ACET?

According to the Biotechnology industry distribution chart, Cue Biopharma ranks #722 out of 831 companies for Beneish M-Score. This places Cue Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Beneish M-Score for a Biotechnology company?

A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Beneish M-Score mean?

A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Cue Biopharma and its competitors. Cue Biopharma's current Beneish M-Score is 1.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cue Biopharma stock overvalued right now?

Based on GuruFocus' analysis, Cue Biopharma (CUE) is currently considered Possible Value Trap. The stock's GF Value™ is $62.11, compared to a current price of $25.94 — trading 58.2% below its estimated fair value. The current Beneish M-Score is 1.03. Cue Biopharma's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Beneish M-Score calculated?

Beneish M-Score is calculated from a company's financial statements. For Cue Biopharma (CUE), the current Beneish M-Score is 1.03 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cue Biopharma (CUE) Overvalued in 2026?

Based on GuruFocus' analysis, Cue Biopharma stock appears to be undervalued. The current stock price of $25.94 is trading 58.2% below its estimated GF Value™ of $62.11. GuruFocus considers Cue Biopharma to be Possible Value Trap.

Key valuation signals for CUE:

Beneish M-Score: 1.03
GF Value™: $62.11 vs. price of $25.94 (58.2% below fair value)
GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the CUE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cue Biopharma Business Description

Industry Healthcare Biotechnology

Comparable Companies TELO ACET AARD OKYO SGMO ANIX PYPD LONA ICCC NRXS VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 1UC0:Germany

Address 40 Guest Street, Boston, MA, USA, 02135

Website https://www.cuebiopharma.com

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

59GF Score

Get the complete analysis for CUE

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.94

Price

$62.11

GF Value

View CUE Analysis

See Beneish M-Score data for all stocks →